Global Ophthalmoplegia Market Outlook 2030

  • Product Code:
    RP-ID-10059322
  • Published Date:
    14 Sep 2021
  • Region:
    Global
  • Pages:
    143
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-12

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

The Research Report is Updated with 2020 Base Year, 2021 Estimated year and Forecast till 2030 with Market Insights.


With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2020 as base year, 2021 as estimated year and forecast to 2030. This will have market drivers, recovery rate in the market, insights and competitive analysis.



Market Overview:

In 2021, the global ophthalmoplegia market is likely to be USD 40 billion. It is expected to expand at a compound annual growth rate (CAGR) of 7% between 2022 and 2030. Peoples awareness of ophthalmological diseases is constantly improving, and progress is constantly being made in terms of technology. Some major factors that are expected to accelerate market growth.

The prevalence of eye-related diseases such as diabetic retinopathy, macular degeneration and presbyopia is expected to continue to increase, which is expected to drive market growth during the forecast period. For example, according to the National Eye Institute, the number of American citizens with AMD is expected to increase from 2.07 million in 2030 to 5.44 million in 2050.

Taking the United States as an example of diabetic retinopathy, the total number of cases is expected to reach 14.6 million by 2050. In addition, ophthalmic pharmaceutical companies are taking strategic initiatives such as collaborations, acquisitions and partnerships to expand their product portfolios through new clinical stage candidates, which is expected to drive the market. For example, in November 2019, Aerie Pharmaceuticals, Inc. acquired Avizorex Pharma, S.L., a Spanish ophthalmic pharmaceutical company, which is dedicated to developing dry eye products. Avizorex Pharma, S.L. has completed the Phase 2a clinical trial of AVX-012 in the treatment of dry eye patients with its main product candidate in early 2020.

The acquisition is expected to expand Aeries footprint in the ophthalmology field. Gene therapy is beneficial to the diagnosis and treatment of hereditary ophthalmological diseases, retinal neurovascular diseases and retinoblastoma. Therefore, more research is needed to optimize and expand the application of gene therapy in ophthalmic indications.

In December 2017, Spark Therapeutics received FDA approval for the first gene therapy drug Luxturna (voretigene neparvovecrzyl) for ophthalmology. This medicine is suitable for retinitis pigmentosa and Leber congenital amaurosis. Luxturna is likely to enjoy the advantage of being a pioneer in the field of gene therapy, which is the main factor driving the ophthalmic drug market.


Drug category insight: The anti-VEGF (vascular endothelial growth factor) market segment dominates the ophthalmic drug market and will account for the largest revenue share in 2020, at 30%, due to high adoption rates and global market participation with a broad product portfolio The existence of the person.

The growth of this segment is mainly due to the strong commercial returns of Lucentis (ranibizumab), Avastin (bevacizumab) and Macugen (Pegaptanib). In addition, several companies are conducting clinical studies to develop a new anti-inflammatory drug for dry eye, thereby driving market growth. For example, in August 2019, OKYO Pharma Ltd. completed a preclinical study and found that OK-113 showed effective anti-inflammatory activity in an experimental model of dry eye in mice. The preclinical efficacy data of OK-113 is expected to be used in the treatment of dry eye disease in 2020.

DISEASE INSIGHTS:

The retinal diseases sector dominates the ophthalmic drug market and will account for the largest revenue share in 2020, at 33.5%. The existence of a strong combination of products and the increase in sales are expected to be one of the main factors driving the market development of ophthalmic drugs for retinal diseases.

The market during the forecast period. For example, in 2017, Graybug Vision, Inc. launched a phase 1/2 trial of GB-102 for the treatment of wet age-related macular degeneration (AMD). GB-102 is a new long-acting formulation of sunitinib malate injection. In addition, the increase in COVID-19 and COVID-19-related eye disease cases is expected to drive market growth. For example, according to data published in the Indian Journal of Ophthalmology, it was found that in China, 31.6% of COVID-19 patients had eye involvement, and 91.7% of COVID-19 patients tested positive for related conjunctivitis.

ADMINISTRATION ROUTE INFORMATION:

The topical administration route dominates the ophthalmic drug market, accounting for the largest share of revenue, 61% in 2020, and is expected to continue to dominate during the forecast period. The existence of strong products in the product portfolio and the increase in sales of ophthalmic drugs for retinal diseases are expected to be one of the main factors driving market development during the forecast period. Market growth.

For example, Bausch & Lomb launched the PreserVision AREDS 2 vitamin mini eye gel for the treatment of advanced AMD in the United States in October 2019.

DOSAGE FROM INSIGHT:

The eye drops segment dominates the ophthalmic drug market, with the largest revenue share in 2020 at 33%. This section is driven by the ease of use and high compliance of some patients. In addition, the development of eye drops for the treatment of rare eye diseases with low prevalence but devastating effects on patients is expected to drive the market. For example, in August 2018, Dompé U.S. received the US FDA approval of Oxervate (cenegermin) for treatment. It is a topical eye drop therapy used to treat neurotrophic keratitis.

In addition, the existence of advanced technologies for the delivery of ophthalmic drugs to improve physicochemical stability and bioavailability is expected to drive market growth. For example, in October 2019, Sun Pharmaceutical Industries Ltd. launched CEQUA (cyclosporine 0.09 eye drops) for patients with keratoconjunctivitis sicca in the United States. CEQUA is provided with Nanoparticle Technology (NCELL) to improve the bioavailability and physicochemical stability of cyclosporine to improve the penetration of eye tissues.

PRODUCT TYPE INSIGHT:

The prescription drug segment dominates the ophthalmic drug market and will account for the largest revenue share in 2020, at 57%. Increased safety and effectiveness of ophthalmic drugs and higher prices are expected to drive market growth.

The over-the-counter market is expected to show a strong growth rate during the forecast period. It is expected that in the near future, the availability of over-the-counter products that increase patient visits will accelerate market growth.

For example, in July 2020, the US FDA approved Alcon’s Pataday (OTC 0.7% Ophthalmic Solution) for the treatment of eye allergies. Previously, it was prescribed under Pazeo's name. The development of this OTC ophthalmic solution is expected to increase the number of patients in the Pataday product portfolio.

REGIONAL INFORMATION:

North America dominates the market, with the largest revenue share in 2020, at 38%, thanks to excellent medical infrastructure and high consumer awareness. In addition, the presence of major players such as Pfizer and Alcon in the region is expected to further promote market growth. For example, in February 2020, Alcon was approved by the US FDA to sell Pataday Once Daily Relief and Pataday Twice Daily Relief in the US without a prescription.

The Pataday brand is used to relieve itching and eye allergies. During the forecast period, the Asia-Pacific region is estimated to be the fastest growing region in the market. The increasing burden of ophthalmic diseases and increased consumer awareness are expected to drive market growth in the Asia-Pacific region. Local companies are participating in strategic initiatives to develop and market new treatment options for patients. In turn, this is expected to drive market growth.

For example, in February 2020, Bridge Biotherapeutics, Inc. acquired an early drug candidate for the treatment of posterior eye disease from Konkuk University (KU). Candidate drugs are inhibitors of target proteins and have not yet been disclosed.

MAJOR COMPANIES AND MARKET SHARE INSIGHTS:

Major companies focus on the research and development of new drugs to cope with the increasing prevalence of eye diseases. For example, in June 2020, Novartis received the US FDAs Biovu (brolucizumab) label update approval.

The update includes additional safety information related to retinal vessel occlusion and retinal vasculitis. This is expected to help doctors make informed decisions about the use of Beovu. Some of the major players in the ophthalmic drug market include: Alcon Johnson & Johnson Services, Inc. Bausch Health Allergan Pfizer, Inc. Bayer AG Santen Pharmaceutical Co. Ltd., Genentech, Inc. Novartis AG Reggeneron Merck & Co. Coherus Biosciences, the company

MARKET SEGMENTS COVERED BY THE REPORT:

The report forecasts global, regional and national revenue growth, and analyzes the latest industry trends in each market segment from 2022-2030. For the purpose of this research, Kenneth Research has subdivided global ophthalmology. A report on the drug market by drug category, disease, route of administration, drug form, product type, and region: Drug category outlook (revenue, million US dollars, 2022-2030), millions of dollars, 2022-2030) Dry Eye Ocular Subcon junctivalIn travi trea lRetrobul barIntracameral Systemic Medications, product type-Olook 20 million US dollars (2017) OTC drugs, 28 million US dollars of prescription drugs.

"


Geography Analysis:


The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports